Zevra Therapeutics Inc

Research Zevra Therapeutics Inc (ZVRA) on Bullrun: valuation model: 44.0% undervalued, market cap USD 828.20M, P/E 6.5. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerZVRA
ExchangeNASDAQ
CountryUnited States
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
Valuation signal44.0% undervalued
Market capUSD 828.20M
P/E6.5
Financial periodFY2025
RevenueUSD 106.47M
Revenue growth350.9%
Net incomeUSD 83.23M
Free cash flow-USD 2.43M

Valuation Snapshot

Bullrun's latest valuation model marks Zevra Therapeutics Inc as 44.0% undervalued; latest market cap is USD 828.20M; P/E is 6.5.

About Zevra Therapeutics Inc

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy.

Frequently asked questions

Is Zevra Therapeutics Inc overvalued or undervalued?

Bullrun's valuation model currently marks Zevra Therapeutics Inc as 44.0% undervalued.

What is Zevra Therapeutics Inc's market cap?

Zevra Therapeutics Inc's market capitalization is USD 828.20M.

What is Zevra Therapeutics Inc's P/E ratio?

Zevra Therapeutics Inc's price-to-earnings (P/E) ratio is 6.5.